The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy

• Váldodahkkit: Changjing Cai (Dahkki), Qingqing Luo (Dahkki), Yihan Liu (Dahkki), Yinghui Peng (Dahkki), Xiangyang Zhang (Dahkki), Zhaohui Jiang (Dahkki), Ziyang Feng (Dahkki), Yaru Qi (Dahkki), Yan Gao (Dahkki), Yongting Liu (Dahkki), Ping Liu (Dahkki), Yihong Chen (Dahkki), Cao Guo (Dahkki), Hong Shen (Dahkki), Shan Zeng (Dahkki), Ying Han (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

There are many treatments for metastatic colorectal cancer (mCRC). Among them, uncertainty remains especially concerning the clinical benefit of different regimens for left-sided RAS wild-type (WT) mCRC in the triple-drug therapy era. No studies have been conducted to answer this critical clinical i...